Southern Brazil has one of the highest incidences of childhood adrenocortical tumors (ACT), occurring 10-15 times more frequently than worldwide estimates. The reasons for this increase remain elusive. In an attempt to further characterize the genetic changes in childhood adrenocortical tumors, we recently detected a consistent gain of 9q (or a portion of it) in 8/9
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Introduction
The incidence of childhood adrenocortical tumors (ACT) is 10-15 times greater in Southern Brazil, particularly in the state of Paraná, as compared to the rest of the world (3.4-4.2 cases/million in southern Brazilian states compared to 0.3 cases/million worldwide). The molecular basis of this disease remains poorly understood, despite several studies investigating the role of particular genes in adrenal tumorigenesis (1) . Using comparative genomic hybridization (CGH), we recently evaluated a group of 9 cases of pediatric ACT from southern Brazil and identified a recurrent pattern of chromosomal aberrations. Gain of 9q or a portion of it emerged as the most consistent finding: 8/9 cases showed this gain and a high level copy number increase (amplification) of 9q34 was detected in five of the eight cases (2) . Interestingly, a similar study conducted in the UK showed gain/amplification of 9q34 in 10/11 childhood adrenocortical tumors (3) . Other studies of adult ACT have also shown frequent gains involving that same chromosomal region (4) . Chromosomal segments showing gain/amplification by CGH are generally sites of amplified genes, and gene amplification is one of the ways in which oncogene activation is achieved. Clearly, identification of such genes and characterization of their mechanism of action and its timing is critical to better understand the process of tumorigenesis for a given tumor.
Steroidogenic factor 1 (SF-1) is an orphan member of the nuclear receptor family of transcription factors and plays an important role in endocrine function, including the regulation of steroid hydroxylases and the transcription of an array of genes involved in reproduction, male sexual differentiation, and the development and function of the adrenal cortex (5, 6, 7, 8) . SF-1 maps to 9q33.3, a chromosomal region which we and others have identified as showing a 5 gain/amplification in a high percentage of cases with childhood adrenocortical tumors (2, 3) .
Studies in SF-1 knockout mice have shown that the adrenal cortex became hypoplastic some time after embryonic development (9, 10) and SF-1 was also shown to be essential for the residual adrenal gland growth after unilateral adrenalectomy (11) . In humans, the adrenal cortex becomes hypoplastic after birth. Volume of the fetal zone (FZ) of the human adrenal cortex rapidly involutes after birth decreasing from 70% to 3% of the total adrenal volume. (12) . The finding of 9q gain in both our previous work and in the study of James et al in childhood ACT as well as in other studies of adult ACT (4), prompted us to conduct the present investigation in order to identify potential candidate genes involved in childhood adrenocortical tumorigenesis.
Because of the intense steroidogenic activity in most childhood cases of ACT, we have investigated SF-1 on 9q33.3 as one of the amplified candidate genes. We used FISH analysis to identify SF-1 amplification in the group of 9 childhood adrenocortical tumors previously analyzed using CGH.
Childhood ACT, in contrast to ACT from adults and many other types of cancer, usually occurs in individuals with germline TP53 mutations (13) . We have previously reported a germline point mutation of TP53 encoding an R337H amino acid substitution combined with somatic loss of the second TP53 allele occurring in 35 of 36 childhood adrenocortical tumors studied from Southern Brazil (14) . In addition, we have evaluated 432 normal individuals from Southern Brazil for the presence of the R337H TP53 mutation and none found to be a carrier (data not shown). TP53 maps to chromosome 17p13.1 and its protein consists of four distinct domains: an N-terminal transactivation domain, a central DNA-binding domain, a tetramerization domain (where Arginine 337 is located) and a C-terminal regulatory domain.
Arginine 337 forms a salt bridge with aspartic acid 352 across the helix-helix interface to form 6 the tetramer. For this reason, we also evaluated our samples for the presence of that common germline TP53 point mutation and for the loss of the wild type TP53 allele. This is a follow-up study to our previous work and to other studies showing that 9q is a hotspot for amplification in ACT. Because SF-1, which is localized to this region, plays an important role in the development and function of the adrenal cortex, here we investigate its amplification in ACT. Table 1 . The tumors were classified as adenomas or carcinomas according to conventional pathological criteria, as previously described (15) . Eight tumors were primary and one was a secondary local recurrent tumor (diagnosed almost 2 years after the resection of the primary tumor). All patients presented with signs and symptoms due to elevated serum levels of androgens and/or glucocorticoids, and were described as having functional tumors. Severity of the clinical manifestations was generally proportional to hormone levels, and to the time between the day of diagnosis and the first documentation of any sign of the disease. Five patients presented only with virilization while the other 4 presented with virilization plus Cushing's syndrome. Six of the tumors were classified as carcinoma while three were adenomas (Table 1) .
Recurrence was noted only in patient # 2 (nine relapses in a period of 5 years, followed by patient death). Patient # 3 was admitted with stage III disease and was operated upon, but developed a large vena cava thrombus that extended to the right atrium. Eight cycles of chemotherapy (ifosfamide, carboplatin, etoposide and mitotane) resulted in almost complete atrophy of the thrombus but the patient died in the intensive care unit as a result of complications 8 of tracheostomy. Complete remission (defined as the complete macroscopic and microscopic tumor resection, absence of distant metastasis and normalization of all clinical features and laboratory values) was documented for all patients who were alive at the time of the report (7/9 patients) representing more than 5 years of survival without local or distant relapse.
Fluorescence in situ hybridization (FISH)
To evaluate the copy number of the SF-1 gene, we designed a FISH probe consisting of a bacterial artificial chromosome (BAC) clone containing sequences of the SF-1 gene: RP11-91G7 (BACPAC Resources, Oakland, CA). BAC clone DNA was prepared and labeled with biotin-11-dUTP (Roche, USA) using nick translation as previously described (16 was H&E stained and histologically examined to confirm the presence of tumor tissue and a consecutive 4 µm paraffin section was evaluated by FISH using the SF-1 FISH probe as described earlier (16) . In brief, the tissue slide was de-paraffinized with Xylene, re-hydrated with decreasing ethanol concentrations and pepsin digested for 90-min, then denatured in 70% formamide/SSC 2x for 4 min at 80˚C. After overnight hybridization with the probe at 37˚C, the slide was washed three times in formamide/SSC 2x (1:1) at 42˚C, and three times in SSC 1x at 42˚C. The biotin-labeled probe was detected with avidin conjugated to fluorescein isothiocyanate Furthermore, the gene was considered to be amplified in those cases where 30% or more of the cells showed 4 or more copies by FISH analysis. In the absence of copy number gain, the presence of 2 FISH signals per cell in at least 50% of the nuclei was considered as normal diploid.
Estimation of R337H TP53 mutation
Four of the nine patients had the entire TP53 gene sequenced using DNA prepared from their lymphocytes, and were found to have the R337H amino acid substitution (14) . The presence of the same mutation was evaluated in the remaining five patients using a previously described PCR/HhaI based assay (14) . Loss of heterozygosity (LOH), described as loss of the wild-type TP53 allele and presence of the R337H TP53 mutation in the tumor genome, was studied in 8 cases as described (14) .
RESULTS
SF-1 FISH analysis:
FISH analysis using the SF-1 specific probe showed increased copy number in 8 of the 9 specimens, while one specimen failed to exhibit copy number gain (majority of cells showing two copies of the gene). Of the 8 patients with increased copy number of the SF-1 gene, 6
showed 4 or more copies of the gene in at least 30% of the cells, and therefore were considered to have SF-1 amplification by FISH. There was an excellent correlation between the CGH findings from our earlier study (2) Amplification of the gene was detected both in the adenomas (2/3 cases) and the carcinomas (3/6 cases); it was also detected in cases presenting with virilization only (4/5 cases) or with both virilization and Cushing's syndrome (1/4 cases). Of note, we did not observe copy number gain in the normal areas of the tissue sections. Table 1 
TP53 mutation and LOH analyses:
The germline R337H mutation was detected in 7 of the 9 patients, and the corresponding tumors showed LOH at the TP53 locus, similar to our findings in an earlier study (14) . In one patient 11 (patient # 9), only tumor DNA was available, which also revealed the presence of the R337H mutation. No DNA was available from normal tissues from this patient and we were therefore unable to determine whether the mutation was present in the germline, nor could we confirm LOH at the TP53 locus in the tumor. Patient # 4, a 23 month old boy with virilization and Cushing's syndrome, did not harbor the germline R337H TP53 mutation as was found in the other patients. However, we cannot rule out the possibility of a different genetic variant in the TP53 gene.
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Discussion:
Studies of adrenocortical tumors in both adults and children have shown that these tumors are associated with a large variety of chromosomal alterations, high level amplifications and losses and gains of DNA material from different chromosomal regions (18, 19, 20, 21) .
However, despite this genetic heterogeneity, these studies have also shown that certain regions of the genome show consistent alterations. 9q34, is among these regions which have been shown to be gained/amplified in both childhood and adult ACT, thus justifying further investigation (2, 3, 4) . The orphan nuclear receptor Steroidogenic factor 1 (SF-1), which plays a key role in endocrine function, maps to 9q33.3. This region is in very close proximity to the common 9q34 amplicon in ACT. The multiple studies that have described this amplicon, including ours, have all used conventional chromosomal CGH (2, 3, 4) . However, because of the lower resolution of conventional chromosomal CGH, this method is incapable of accurately delineating the exact boundaries of amplicons; hence it is very possible that the previously described 9q34 amplicon may include the 9q33.3 region and thus the SF-1 gene (22) .
In the present study, we investigated the possible gain/amplification of the SF-1 gene in childhood ACT. We used FISH to detect copy number changes of the gene in a cohort of nine tumors which we had previously evaluated using CGH. These cases included six carcinomas and three adenomas. CGH showed chromosomal aberrations in all nine cases. But, despite the high number of alterations, we observed a recurrent pattern; the most striking finding was a consistent copy number gain of chromosomal region 9q34 in 8 of the 9 tumors (2). A similar finding of 9q34 gain was independently observed in other studies of both childhood (3) and adult ACT (4). (Table 1) . Our study does not address the question regarding which portion of the SF-1 gene is duplicated. However, we are in the process of collecting fresh frozen ACT tissues to investigate this point in a future study.
Unraveling the complexity behind 9q34 amplification may provide a role that the expression of an amplified gene could play in the pathogenesis of adrenocortical tumors. We originally hypothesized that the 9q34 amplification detected in our study (2) could indicate the site of an oncogene(s) involved in ACT formation, and thus we proposed that amplification of 9q34 could involve aberrant transcripts of the ABL1 oncogene; this possibility was ruled out using Southern blot analysis (data not shown). However the SF-1 gene may not be the only amplified gene in the 9q34 amplicon. Other genes mapped to 9q34 which may play a role in ACT tumorigenesis include the VAV2 oncogene (23), the transforming growth factor-ß receptor-1 gene (TGFBR1), which is an activin A receptor type II-like kinase (24) , the tumor necrosis factor receptor-associated factor-2 gene (TRAF1) (25) , the oncogene 24p3 or lipocalin 2 gene (LCN2/NGAL) (26) , and the retinoid X receptor, alpha (RXRA).
One consequence of the SF-1 gene amplification, particularly if it is associated with high expression of the SF-1 protein, could be an increased steroid hydroxylase activity and steroid production. A recent review of 254 children enrolled in the International Pediatric Adrenocortical Tumor Registry (27) showed that signs of virilization were found in 84.2% of patients, consistent with those of other reports from other continents (27, 28, 29, 30, 31 lesions, may lead to tumor formation. In the present study, the germline R337H TP53 mutation and the somatic loss of the wild type TP53 allele were found in 7 of the 9 patients studied. The most striking association between germline TP53 mutations and cancer is found in cases of childhood ACT (13) . We believe that the germline R337H TP53 mutation combined with LOH (14) under certain conditions of pH and temperature (35) may occur during the development of the adrenal cortex and thus generate ACT. Of the 8 tumors with SF-1 increased copy number by FISH, six had the germline R337H TP53 mutation and somatic loss at the TP53 locus (wild-type allele) in the tumor, and one (patient # 9) had the R337H TP53 mutation in the tumor (this case was not tested for germline mutation). The only case with normal copy number of the SF-1 gene, also showed the TP53 germline mutation and LOH. Chromosomal instability caused by TP53 15 dysfunction is well documented, in addition, the loss of the wild type TP53 was shown to predispose to gene amplification and altered cell cycle arrest (36) . We believe that the germline R337H TP53 mutation and the somatic loss of the wild-type allele can contribute to genomic alterations and increased SF-1 copy numbers. Further studies are needed to clarify whether the TP53 mutation and 9q34 amplification, including SF-1 amplification, are part of a cascade of events leading to ACT oncogenesis, similar to what was reported in other tumors, such as in the multi-step progression of colorectal cancer (37) . This is the first study showing an association between an increased copy number of the SF-1 gene and adrenocortical tumors. The significance of this observation needs to be further investigated using a larger cohort of both pediatric and adult cases. Because this gene is detected at the earliest stages of development of the urogenital ridge, where both the gonads and the adrenal cortex are derived, and because this expression is maintained throughout development up till adult life (7), further studies examining the mechanisms and consequences of the amplification of this gene in ACT are critical to a better understanding of the onset and progression of this disease. 
